Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

NCT03763877 is registered in ClinicalTrials.gov with Poxel SA as lead sponsor.

NCT NCT03763877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03763877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Lead sponsor
Poxel SA
Phase
Phase 2
Overall status
Completed
Start date
March 29, 2019
Completion date
August 10, 2020
Enrollment
121 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver